This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bodgen, A. E. Articles by LePage, D. J. Search for Related Content PubMed PubMed Citation Articles by Bodgen, A. E. Articles by LePage, D. J.

Response of Human Lung Tumor Xenografts to Treatment with a Somatostatin Analogue (Somatuline)

Biomeasure Incorporated, Hopkinton, Massachusetts 01748 [A. E. B., J. E. T., J-P. M., D. J. L.], and Peptide Research Laboratories, Department of Medicine, Tulane University Medical Canter, New Orleans, Louisiana 70112 [D. H. C.]

Four human small cell lung carcinomas, NCI-H69, NCI-N417, NCI-H345, LX-1, and a non-small cell lung carcinoma, H-165, implanted s.c. as tumor xenografts in athymic nude mice, were treated with Somatuline (BIM-23014C), an endocrinologically potent octapeptide analogue of somatostatin. All tumors responded, although in varying degrees, with percentage of test/control values ranging from 3 to 88. Somatuline administered as a perilesional infusion effectively inhibited xenograft growth inducing prolonged remissions. When treatment was terminated, some tumors regrew, suggesting antimitogenic activity rather than cytocidal. Absence of observable systemic or local toxicity during prolonged treatment would support this conclusion and suggest the feasibility of long term maintenance therapy with a resultant extended survival.

¹ To whom requests for reprints should be addressed, at Biomeasure Incorporated, 9–15 Avenue E, Hopkinton, MA 01748.

Received 11/20/89. Revised 3/ 6/90.

This article has been cited by other articles:

				S. Faiss, U.-F. Pape, M. Bohmig, Y. Dorffel, U. Mansmann, W. Golder, E. O. Riecken, and B. Wiedenmann Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors--The International Lanreotide and Interferon Alfa Study Group J. Clin. Oncol., July 15, 2003; 21(14): 2689 - 2696. [Abstract] [Full Text] [PDF]

				H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				T. J. Gillespie, A. Erenberg, S. Kim, J. Dong, J. E. Taylor, V. Hau, and T. P. Davis Novel Somatostatin Analogs for the Treatment of Acromegaly and Cancer Exhibit Improved In Vivo Stability and Distribution J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 95 - 104. [Abstract] [Full Text]